In addition, we noted a decreased expression of METTL14 in METTL3/METTL14 complex but not an increase of demethylase FTO or ALK in pazopanib resistant ccRCC cells (Fig. 5C), implying METTL14 reduction may account for IGFL2-AS1 demethylation. This evidence concerns the gene FTO and nonpapillary renal cell carcinoma.